Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
WVE
WVE
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
WVE News
Wave Life Sciences' Weight Loss Drug Fails Phase 1 Study
Apr 01 2026
NASDAQ.COM
Wave Life Sciences Phase 1 Trial Results Disappoint Investors
Apr 01 2026
Fool
Wave Life Sciences Shares Surge 9.5% Amid Trading Volume Spike
Apr 01 2026
NASDAQ.COM
WAVE LIFE SCIENCES LTD: WEDBUSH REDUCES TARGET PRICE FROM $35 TO $15
Mar 27 2026
moomoo
Wave Life Sciences Shares Plunge 49.59% After Disappointing Data
Mar 26 2026
Fool
Wave Life Sciences Shares Plunge Nearly 50% After Disappointing Data
Mar 26 2026
NASDAQ.COM
Wave Life and Golar LNG See Active Options Trading
Mar 26 2026
NASDAQ.COM
Wave Life Sciences Shares Plunge Nearly 50% on Trial Data Disappointment
Mar 26 2026
seekingalpha
WVE-007 Trial Data Triggers Stock Volatility
Mar 26 2026
stocktwits
Johnson Fistel Investigates Wave Life Sciences for Potential Investor Claims
Mar 26 2026
Globenewswire
Wave Life Sciences' Obesity Drug Data Disappoints Investors
Mar 26 2026
stocktwits
Wave Life Sciences Shares Plunge 57% on WVE-007 Trial Data
Mar 26 2026
seekingalpha
WVE-007 Clinical Trial Data Shows Significant Improvements
Mar 26 2026
Newsfilter
WAVE Life Sciences Ltd to Launch Phase 2A INLIGHT and New WVE-007 Trials as Incretin Add-On in 2026
Mar 26 2026
moomoo
FDA Rejects Multiple Experimental Drug Applications, Raising Investor Concerns
Mar 06 2026
CNBC
FDA Drug Approval Uncertainty Intensifies
Mar 06 2026
Newsfilter
Show More News
